Skip to main content

Table 2 HLA-DQA1 , HLA-DQB1, and HLA-DRB1 allele frequencies in PM and DM patients and controls

From: HLA class II alleles may influence susceptibility to adult dermatomyositis and polymyositis in a Han Chinese population

Loci/alleles

DM

PM

Myositis with ILD

Myositis with dysphagia

Control

Control vs. indicated patients ( p; OR (95% CI))

 

n (%)

n (%)

n (%)

n (%)

n (%)

DM

PM

Myositis with ILD

Myositis with dysphagia

HLA-DRB1

N = 65

N = 19

N = 37

N = 10

N = 113

    

*01

1 (0.77)

0 (0.00)

1 (1.35)

0 (0.00)

5 (2.45)

n/s

n/a

n/s

n/a

*03

4 (3.08)

4 (10.53)

4 (5.41)

1 (5.00)

23 (11.27)

0.011; 0.26

n/s

n/s

n/s

(0.06–0.81)

*04

17 (13.08)

6 (15.79)

15 (20.27)

2 (10.00)

22 (10.78)

n/s

n/s

0.011; 2.82

n/s

(1.15–6.76)

*07

27 (20.77)

1 (2.63)

14 (18.92)

6 (30.00)

27 (13.24)

0.011; 2.26

n/s

n/s

0.011; 4.78

(1.12–4.59)

(1.03–24.42)

*08

13 (10.00)

4 (10.53)

7 (9.46)

2 (10.00)

17 (8.33)

n/s

n/s

n/s

n/s

*09

20 (15.38)

2 (5.26)

3 (4.05)

3 (15.00)

26 (12.75)

n/s

n/s

n/s

n/s

*10

2 (1.54)

1 (2.63)

2 (2.70)

0 (0.00)

3 (1.47)

n/s

n/s

n/s

n/a

*11

3 (2.31)

3 (7.89)

2 (2.70)

0 (0.00)

9 (4.41)

n/s

n/s

n/s

n/a

*12

20 (15.38)

7 (18.42)

14 (18.92)

1 (5.00)

22 (10.78)

n/s

n/s

0.021; 2.52

n/s

(1.02–6.07)

*13

7 (5.38)

1 (2.63)

2 (2.70)

1 (5.00)

8 (3.92)

n/s

n/s

n/s

n/s

*14

2 (1.54)

3 (7.89)

1 (1.35)

2 (10.00)

9 (4.41)

n/s

n/s

n/s

n/s

*15

10 (7.69)

4 (10.53)

7 (9.46)

1 (5.00)

29 (14.22)

n/s

n/s

n/s

n/s

*16

4 (3.08)

2 (5.26)

2 (2.70)

1 (5.00)

4 (1.96)

n/s

n/s

n/s

n/s

HLA-DQA1

N = 67

N = 20

N = 39

N = 12

N = 110

    

*0101

9 (6.72)

0 (0.00)

5 (6.41)

1 (4.17)

11 (5.00)

n/s

n/a

n/s

n/s

*0102

18 (13.43)

10 (25.00)

16 (20.51)

4 (16.67)

44 (20.00)

n/s

n/s

n/s

n/s

*0103

26 (19.40)

6 (15.00)

10 (12.82)

6 (25.00)

28 (12.73)

n/s

n/s

n/s

n/s

*0104

22 (16.42)

4 (10.00)

11 (14.10)

4 (16.67)

18 (8.18)

0.011; 2.58

n/s

n/s

n/s

1.18–5.64)

*0201

1 (0.75)

2 (5.00)

1 (1.28)

0 (0.00)

1 (0.45)

n/s

n/s

n/s

n/a

*0301

44 (32.84)

9 (22.50)

26 (33.33)

9 (37.50)

85 (38.64)

n/s

n/s

n/s

n/s

*0302

1 (0.75)

0 (0.00)

0 (0.00)

0 (0.00)

1 (0.45)

n/s

n/a

n/a

n/a

*0401

1 (0.75)

2 (5.00)

2 (2.56)

0 (0.00)

3 (1.36)

n/s

n/s

n/s

n/a

*0501

11 (8.21)

6 (15.00)

6 (7.69)

0 (0.00)

28 (12.73)

n/s

n/s

n/s

n/a

*0507

1 (0.75)

0 (0.00)

0 (0.00)

0 (0.00)

0 (0.00)

n/a

n/a

n/a

n/a

*0601

0 (0.00)

1 (2.50)

1 (1.28)

0 (0.00)

1 (0.45)

n/a

n/s

  

HLA-DQB1

N = 67

N = 17

N = 37

N = 10

N = 113

    

*0201

31 (23.48)

6 (16.67)

16 (21.62)

5 (25.00)

44 (19.47)

n/s

n/s

n/s

n/s

*0301

20 (15.15)

9 (25.00)

15 (20.27)

0 (0.00)

35 (15.49)

n./s

n/s

n/s

n/a

*0302

9 (6.82)

2 (5.56)

7 (9.46)

1 (5.00)

12 (5.31)

n/s

n/s

n/s

n/s

*0303

24 (18.18)

2 (5.56)

5 (6.76)

5 (25.00)

43 (19.03)

n/s

n/s

0.011; 0.25

n/s

(0.07–0.73)

*0401

6 (4.55)

2 (5.56)

6 (8.11)

1 (5.00)

7 (3.10)

n/s

n/s

n/s

n/s

*0402

0 (0.00)

1 (2.78)

1 (1.35)

0 (0.00)

1 (0.44)

n.a.

n/s

n/s

n/a

*0501

1 (0.76)

2 (5.56)

3 (4.05)

0 (0.00)

8 (3.54)

n/s

n/s

n/s

n/a

*0502

5 (3.79)

2 (5.56)

5 (6.76)

0 (0.00)

7 (3.10)

n/s

n/s

n/s

n/a

*0503

4(3.03)

1 (2.78)

0 (0.00)

2 (10.00)

8 (3.54)

n/s

n/s

n/a

n/s

*0601

20 (15.15)

7 (19.44)

11 (14.86)

3 (15.00)

33 (14.60)

n/s

n/s

n/s

n/s

*0602

4 (3.03)

2 (5.56)

2 (2.70)

2 (10.00)

16 (7.08)

n/s

n/s

n/s

n/s

*0604

5 (3.79)

0 (0.00)

2 (2.70)

0 (0.00)

5 (2.21)

n/s

n/a

n/s

n/a

*0608

3 (2.27)

0 (0.00)

1 (1.35)

1 (5.00)

7 (3.10)

n/s

n/a

n/s

n/s

  1. n/s: not significant; n/a: not applicable; 1 p corr greater than 0.05; ILD: interstitial lung disease.
Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us